Immuron (IMC)

Shares / Stock Code

IMC

Stock Exchange / Sharemarket

ax

Immuron (IMC) is a biotechnology R&D company focussed on the development, manufacture and commercialisation of nutraceutical, pharmaceutical and related therapeutic technology products, primarily for use in and by, humans. IMC developes natural pharmaceuticals from dairy fractions and colostrum. Investors can trade Immuron shares on the Australian Stock Exchange (ASX).

IMC listed on the Australian stock market in April 1999. The company has formed several strategic alliances within Australia, Taiwan and North America. IMC also has associations with the health research community in Melbourne and the dairy industry in Australia. In December 2008, the company changed its name and ASX code from Anadis (ANX) to Immuron (IMC).

IMC has a deliberate strategy to commercialise early in the product development cycle. As R&D progresses, efficacious products, including over-the-counter pharmaceuticals and/or functional foods, are brought to market early. The company develops natural pharmaceuticals from dairy fractions and colostrum, the antibody-rich milk produced from cows during the first 24 hours after giving birth.

Potential customers for Immuron's products include travellers and sufferers of osteoporosis and gastric disorders. IMC competes with other biotechnology companies producing treatments for the same disorders. Immuron leverages advanced dairy industry technology and a significant body of human clinical studies to produce safe, oral formulations of antibodies and other bioactive proteins of value. Immuron's antibodies and proteins are harvested from the first postpartum milking of dairy cattle (colostrum or “immune milk”).

These cattle have previously been immunized with Immuron's proprietary vaccines before calving, and have been monitored to assure vaccine immunogenicity. Primary bovine colostrum (BCP) from these cattle have a naturally high concentration of immunoglobulins as well as a high natural concentration of other proteins, and include antigen target immunoglobulins specific to the vaccine antigen company have used.

Immuron works with world class academic and governmental health institutions to improve their vaccines, characterize their bioactives, and demonstrate clinical efficacy and safety for their products. As a result, company hold an ever-expanding intellectual property portfolio to maximize potency and clinical use of Immuron's novel formulations targeting specific diseases.

This includes issued patents and patent filings concerned with preparation of their vaccines, collection of colostrum, economic processing of their bioactives, oral delivery of their products, specific mechanisms of disease prevention and treatment unique to their approaches.